

Occurrence and probiotic properties of *Lactobacillus* spp. of maternal breast milk in the Uyghur, Xinjiang China, at different lactation stages

Xiaojuan Li

Shihezi University

Xu Li

Shihezi University

Yan Zhang

Shihezi University

Fengwei Tian

Shihezi University

Yongqing Ni (✉ niyqlzu@sina.com)

Research article

Keywords: Lactobacillus, Breast milk, Antibiotic resistance, Probiotic properties

Posted Date: January 29th, 2020

DOI: <https://doi.org/10.21203/rs.2.22239/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Background

As a secure vehicle of probiotics, breast milk can provide babies with the *Lactobacillus* which can not only colonize and inhibit the pathogenic bacterial infection in infant's intestines. The purpose of this study was to assess the occurrence and probiotic properties of *Lactobacillus* spp. of maternal breast milk in the Uyghur population, Xinjiang China, by using culture method.

Results

Based on repetitive genomic fingerprinting PCR (rep-PCR), a total of 198 isolates of *Lactobacillus* from 31 different lactation of breast milk samples of Uyghur in kashi region of Xinjiang were classified into 11 genotypes, which were identified as *Lactobacillus fermentum* (82 isolates, prevalence: 61.3%, mean relative abundance: 45.4%, genotype: 3), *Lactobacillus brevis* (75, 41.9%, 38.1%, 4), *Lactobacillus oris* (37, 32.3%, 15.1%, 3) and rare *Lactobacillus vaginalis* (4, 9.7%, 1.4%, 1). From colostrum to mature milk, the number and species of *Lactobacillus* showed an uptrend, from mature milk to late milk, a downside was found in *Lactobacillus*. The relative abundance of *L. fermentum* decreased throughout lactation, while *L. brevis* showed an opposite trend. Three isolates were randomly selected for each genotype to estimate antimicrobial activity (33 isolates in total). Among the isolates, 20 isolates exhibited broad antibacterial spectrum with inhibition halos >10 mm against most indicator pathogens, which were selected for assessing probiotic properties. Nineteen isolates showed the resistance to vancomycin and co-trimoxazole, and KM66 (*L. brevis*) was resistant up to 5/8 antibiotics. KM147 (*L. brevis*) and Y3 (*L. fermentum*) strains were selected as potential probiotics by combining lysozyme, acid and bile salt tolerance.

Conclusion

Species composition and prevalence of *Lactobacillus* varied with the study subjects throughout lactation phase. The deliberately selected *Lactobacillus* strains from breast milk may have a great potential as probiotics to inhibit pathogen infection in infants.

Background

With the improvement of people's living quality and the constant pursuit of healthy food, there is a growing interest in probiotics, especially the lactic acid bacteria (LAB) viz. *Lactobacillus* spp., *Bifidobacterium* spp., etc (1). It is well known that *Lactobacillus* is a fabulous probiotic LAB, a gram-positive, non-spore forming, facultative anaerobic bacteria which plays a significant role not only in fermented dairy products, but also in beverages and silages (2). Particularly, the *Lactobacillus* has been demonstrated to provide many health benefits including inhibition against the infection of pathogenic bacteria, enhancing the body's immunity as well as preventing the occurrence of bacterial flora imbalance and bacterial displacement (3–5).

It has been found that probiotics in infants gut primarily come from breast milk and the mother's gut and vagina. Given the risk of antibiotic resistance, breast milk is deemed to be a more secure source of probiotics relative to other environments (6). As a vehicle of probiotics, breast milk has the mother-to-infant transfer of some bacteria that can colonize in the infant's intestines (7). Probiotics such as *Lactobacillus* and *Bifidobacterium* in breast milk have profound effects on the development of intestinal flora and immune system of infants (8). Additionally, the microbiota of breast milk is generally complex and variable: it reaches the most complex level at the mature milk, and then it stays constant and drops sharply at late milk (9). *Lactobacillus* is abundant in breast milk, among which the most commonly reported are *L. fermentum*, *L. rhamnosus*, *L. salivarius*, etc (7). To date, the occurrence of *Lactobacillus* in different lactation stages of breast milk is not clear. Whether the prevalence of *Lactobacillus* in breast milk is related to different lactation periods is of great significance for understanding the occurrence of *Lactobacillus* in breast milk and the intestinal metastasis of these bacteria in infants. Since most babies are breastfed after birth, and it's confirmed that it can prevent neonatal allergy, malnutrition and infections from breastfeeding (10). Based on its potential probiotic properties, the antimicrobial activity of the *Lactobacillus* isolated from breast milk has become a hotter topic to scientists around the world. Some studies have found that *Lactobacillus* isolated from breast milk has probiotic properties, such as improving intestinal tract, therapeutic effect of diarrhea and adjuvant therapy of some diseases (11). For example, the *L. gasseri* CECT5714 and *L. fermentum* CECT5716, originated from breast milk have been shown to play a crucial role in inhibiting pathogen infection based on the mechanism of producing antimicrobial bacteriocins to compete with pathogens in intestinal tract (12,13).

In addition, breast milk microflora is closely related to human lifestyle, dietary habits, regional differences, delivery mode (14,15). Xinjiang is a large and multi-ethnic residential area with unique Uyghur living habits and food culture. Thus, the breast milk of Uyghur in Xinjiang provide a rich source of unique host for the exploitation and utilization of *Lactobacillus*. In this study, the aim was to assess the occurrence of *Lactobacillus* spp. of maternal breast milk in the Uyghur population, northwestern China, by using culture method, and then evaluate their key probiotic characteristics including antimicrobial activity, antibiotic resistance, lysozyme, acid and bile salt resistance. We hope to screen out *Lactobacillus* probiotics with significant antibacterial properties, and finally apply them to health food after *in vivo* experiments.

Result

Molecular identification and occurrence of *Lactobacillus* in breast milk

Combined with morphology and partial gene sequencing of 16S rRNA, 198 *Lactobacillus* from 31 breast milk samples of different lactation of the Uyghur in kashi region of Xinjiang were identified, which were classified into 11 genotypes based on rep-PCR genotyping. Through BLAST homology analysis (above 97% homology), all the *Lactobacillus* were identified as *L. fermentum* (82 isolates, genotype: 3), *L. brevis* (75, 4), *L. oris* (37, 3) and *L. vaginalis* (4, 1). Meanwhile, *L. fermentum* occurred in 19 out of 31 breast milk samples (prevalence: 61.3%). *L. brevis*, *L. oris* and *L. vaginalis* were isolated from 13/31 (41.9%), 10/31 (32.3%) and 3/3 (9.7%) samples respectively.

According to different lactation period, breast milk samples were divided into five stages, they are colostrum stage A (1–5 postpartum days), mature milk B (15–90 days), late mature milk C (91–300 days), late milk D (301–450 days) and late milk E (451–570 days) (16). As shown in Table 1, during the whole lactation period, the number of lactobacilli in breast milk samples showed a trend of mature milk B > late milk E > late milk C > colostrum A > late mature milk D, and the diversity showed mature milk B = late mature milk C > late milk D > late milk E > colostrum A. At the level of species, the mean relative abundance of *L. fermentum*, *L. brevis*, *L. oris* and *L. vaginalis* in five stages was 45.4%, 38.1%, 15.1% and 1.4% respectively. *L. fermentum* was the dominant species, and only *L. fermentum* was isolated from colostrum A. *L. fermentum*, *L. oris* and *L. vaginalis* had the highest isolation rate (22.2%, 13.6% and 1.5%) in mature milk B, and *L. brevis* had the highest isolation rate (16.7%) in late milk E. The 4 isolates of *L. vaginalis* were isolated from mature breast milk B and late mature milk C. As shown in Fig. 1, *L. fermentum* were identified from all 5 stages of lactation (A-E). Meanwhile, the relative abundance of *L. fermentum* showed a decreasing trend throughout the lactation. On the contrary, the relative abundance of *L. brevis* increased gradually, and reached the highest value (76.7%) in late milk E. Principal component analysis (PCA) (Fig. 2) showed that all shapes were distributed concentratedly and no significant independent population was formed, indicating that populations of *Lactobacillus* isolated during five different lactation periods were similar. According to the dispersion degree of the shape in the figure, the population structure of *Lactobacillus* isolated in later milk D was more similar than that in other stages, while that in mature milk B was vice versa. Three isolates were randomly selected for each genotype to assess probiotic properties (33 isolates in total). The strain ID, genus names and species names were shown in Fig. 3.

Table 1
Distribution of *Lactobacillus* in breast milk during

Age (day)	A (1–5 d)					B (15–150 d)							C (151–300 d)				
Samples	Y4	Y10	Y12	Y6	Y7	KZ13	GL30	GL34	KZ19	GL37	GL28	GL26	KZ14	KZ15	GL27	KZ30	GL2
<i>L. fermentum</i>	1	1	14	–	–	2	6	27	5	4	–	–	4	–	1	2	1
<i>L. brevis</i>	–	–	–	–	–	9	4	–	3	9	–	–	7	3	–	–	–
<i>L. oris</i>	–	–	–	–	–	3	16	3	1	3	1	–	2	4	1	–	–
<i>L. vaginalis</i>	–	–	–	–	–	–	–	1	–	–	2	–	–	1	–	–	–
Total	16					99							26				

L. fermentum: *Lactobacillus fermentum*, *L. brevis*: *Lactobacillus brevis*, *L. oris*: *Lactobacillus oris*, *L. vaginalis*: *Lactobacillus vaginalis*.

Assessment of the antimicrobial activity

The antibacterial property is one of the significant criteria of *Lactobacillus* for screening potential probiotics. It was reported that some *Lactobacillus* strains play a pivotal role in the inhibition of the infection caused by pathogenic bacteria in infants (6,17). In our study, 20 of 33 *Lactobacillus* isolates had broad antibacterial spectrum with inhibition zones > 10 mm against most indicator pathogens, all of which can inhibit *Escherichia coli* (EPEC) O127:K63, *Salmonella enterica* subsp. *enterica* serovar *Typhimurium* and *E. coli* (ETEC). The isolate KM66 (*L. brevis*) exhibited the broadest antibacterial spectrum with an inhibition zone diameter (mm) of 21.36 ± 0.22 , 19.82 ± 0.08 , 18.00 ± 0.06 and 20.41 ± 0.10 against *E. coli* (EPEC), *S. Typhimurium*, *E. coli* (ETEC) and *Listeria monocytogenes* (CGMCC 1.9136) respectively. The KM147 (*L. brevis*) exhibited the largest inhibition zone (15.20 ± 0.28 mm) against *E. coli* (EHEC). The broadest antibacterial spectrum (inhibition zone: 19.87 ± 0.25 mm) against *Salmonella enterica* subsp. *Enterica* (CGMCC 1.10754) was observed with the Y3 (*L. fermentum*). Among *L. oris* strains, GM12-2 exhibited relatively obvious inhibition on all six indicator pathogens (Table 2). Based on broad antibacterial spectrum on indicator pathogens, 20 isolates were selected for further test.

Table 2

In vitro antimicrobial activity of Lactobacillus isolates against pathogenic bacteria with modified agar sandwich overlay method after incubating 24 h at 37 °C.

strain ID	Test organism with Inhibition Zone Diameter mean (mm) ± S.D.						
	E. coli (EPEC) O127:K63 (CICC 10411)	E. coli (ETEC) O78:K80(CICC 10421)	E. coli (EHEC) O157:H7 (CICC 21530)	Listeria monocytogenes (CGMCC 1.9136)	Salmonella enterica subsp. enterica serovar Typhimurium (CICC 10420)	Salmonella enterica subsp. Enterica (CGMCC 1.10754)	average value
KM147	18.00 ± 0.08	16.80 ± 0.18	15.20 ± 0.28	16.65 ± 0.18	18.00 ± 0.16	14.62 ± 0.20	16.55
KM66	21.36 ± 0.22	18.00 ± 0.06	14.81 ± 0.10	20.41 ± 0.10	19.82 ± 0.08	19.80 ± 0.07	19.03
KM86	18.33 ± 0.08	10.20 ± 0.12	9.25 ± 0.05	14.06 ± 0.27	18.24 ± 0.09	15.45 ± 0.09	14.26
GM1-2	16.35 ± 0.04	15.65 ± 0.14	10.25 ± 0.07	10.53 ± 0.07	11.53 ± 0.15	10.00 ± 0.07	12.39
GM3-1	15.65 ± 0.12	17.53 ± 0.05	11.48 ± 0.09	8.75 ± 0.05	10.35 ± 0.05	—	12.75
KM26	11.90 ± 0.17	17.07 ± 0.05	12.43 ± 0.08	9.28 ± 0.05	14.83 ± 0.24	14.50 ± 0.22	13.34
KM165	8.94 ± 0.10	10.65 ± 0.08	16.74 ± 0.04	10.40 ± 0.06	11.90 ± 0.05	11.80 ± 0.10	11.74
KM22	14.83 ± 0.09	14.35 ± 0.28	9.28 ± 0.05	10.03 ± 0.02	11.45 ± 0.18	—	11.99
KM54	14.45 ± 0.07	15.25 ± 0.05	—	9.43 ± 0.05	11.65 ± 0.08	8.98 ± 0.01	11.95
KM15	16.30 ± 0.06	14.88 ± 0.08	9.69 ± 0.05	9.12 ± 0.04	11.45 ± 0.05	—	12.29
KM164	15.33 ± 0.05	14.58 ± 0.08	10.80 ± 0.05	11.30 ± 0.04	10.08 ± 0.08	9.05 ± 0.07	11.86
Y7	11.28 ± 0.08	8.58 ± 0.04	—	—	8.65 ± 0.04	15.08 ± 0.10	10.90
KM176	10.68 ± 0.09	16.55 ± 0.44	10.10 ± 0.01	15.95 ± 0.04	10.28 ± 0.29	9.25 ± 0.04	12.14
GM12-2	12.50 ± 0.04	13.75 ± 0.04	13.28 ± 0.04	14.58 ± 0.50	13.05 ± 0.14	11.43 ± 0.04	13.10
Y3	18.90 ± 0.16	12.73 ± 0.16	9.83 ± 0.07	16.80 ± 0.42	10.41 ± 0.12	19.87 ± 0.25	14.75
KM4	10.78 ± 0.08	12.30 ± 0.04	11.70 ± 0.04	15.31 ± 0.13	13.18 ± 0.08	11.62 ± 0.04	12.46
GM68-2	12.34 ± 0.13	11.00 ± 0.10	13.60 ± 0.04	11.85 ± 0.13	11.62 ± 0.04	11.00 ± 0.01	11.90
KM68	14.43 ± 0.26	14.90 ± 0.19	9.61 ± 0.08	17.95 ± 0.13	9.71 ± 0.07	12.43 ± 0.16	13.17
KM11	8.80 ± 0.06	12.58 ± 0.04	14.43 ± 0.20	13.48 ± 0.16	13.53 ± 0.32	—	12.56
KM50	11.05 ± 0.01	10.90 ± 0.02	—	—	11.00 ± 0.11	—	10.98
KM1	8.53 ± 0.05	9.23 ± 0.04	8.75 ± 0.03	8.58 ± 0.04	8.58 ± 0.05	9.05 ± 0.10	8.79
GM42-2	10.33 ± 0.05	—	—	—	—	9.08 ± 0.09	9.71
GM37-2	—	—	9.95 ± 0.01	—	8.78 ± 0.07	9.13 ± 0.05	9.29
GM59-2	9.80 ± 0.01	9.43 ± 0.06	—	—	—	9.83 ± 0.16	9.68
KM97	9.83 ± 0.06	—	8.60 ± 0.05	—	9.85 ± 0.01	—	9.43
GM33-1	9.98 ± 0.12	—	—	8.58 ± 0.05	8.40 ± 0.04	—	8.99
Y9-1	11.25 ± 0.05	—	8.55 ± 0.06	—	8.73 ± 0.05	11.03 ± 0.09	9.89
GM61-1	8.68 ± 0.04	—	9.10 ± 0.07	—	10.25 ± 0.04	—	9.34
KM122	—	12.00 ± 0.13	8.98 ± 0.03	—	8.93 ± 0.10	—	9.97
KM93	9.30 ± 0.09	—	—	—	—	—	9.30
KM121	8.10 ± 0.07	—	—	—	—	8.15 ± 0.26	8.13
GM42-1	—	—	—	—	8.45 ± 0.30	8.93 ± 0.15	8.69

The diameter of AGAR wafer are 7 mm, — = no activity, ± = standard deviation (S.D), assays were carried out in quadruplication.

strain ID	Test organism with Inhibition Zone Diameter mean (mm) ± S.D.							average value
	E. coli (EPEC) O127:K63 (CICC 10411)	E. coli (ETEC) O78:K80(CICC 10421)	E. coli (EHEC) O157:H7 (CICC 21530)	Listeria monocytogenes (CGMCC 1.9136)	Salmonella enterica subsp. enterica serovar Typhimurium (CICC 10420)	Salmonella enterica subsp. Enterica (CGMCC 1.10754)		
KM13	8.06	—	—	—	—	—	8.06	

The diameter of AGAR wafer are 7 mm, — = no activity, ± = standard deviation (S.D), assays were carried out in quadruplication.

Antibiotic resistance profile

Since the overuse of antibiotics, antibiotic resistance has become one of the important criteria for selecting potential probiotics (18). The antibiotic susceptibility of breast milk Lactobacillus was evaluated by the K-B paper method and results are shown in Table 3. All 20 isolates were found sensitive to ampicillin, rifampicin and tetracycline, and only KM66 was resistant to chloramphenicol. All isolates exhibited antibiotic resistance to vancomycin and co-trimoxazole except KM4 and KM11 respectively. Fifty-five percent of isolates showed resistance to gentamicin (Fig. 4). In particular, KM66 is the most obvious multidrug-resistant isolate with resistance up to five antibiotics (chloramphenicol, gentamicin, co-trimoxazole, penicillin-G and vancomycin).

Table 3
Antibiotic susceptibility of lactobacilli using the K-B paper method after 24 incubation at 37 °C.

antibiotic strain ID	KM147	KM66	KM86	GM1-2	GM3-1	KM26	KM165	KM22	KM54	KM15	KM164	Y7	KM176	GM12-2	Y3
Chloramphenicol (30 µg)	S	R	S	S	S	S	S	S	S	S	S	S	S	S	S
Gentamicin (10 µg)	S	R	S	R	R	S	S	R	R	S	R	R	S	S	S
Co-trimoxazole (25 µg)	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R
Ampicillin (10 µg)	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
Rifampicin (5 µg)	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
Penicillin-G (10 µg)	I	R	R	I	S	I	I	S	S	I	R	S	I	R	S
Tetracycline (30 µg)	S	S	S	S	S	S	S	S	S	S	S	S	S	S	S
Vancomycin (30 µg)	R	R	R	R	R	R	R	R	R	R	R	R	R	R	R

S = sensitive, I = mediating, R = resistant.

Resistance of lysozyme

Assessing their resistance to extreme conditions in the digestive tract is an important criterion for selecting potential probiotics (19,20). The obstacles to overcome, in turn, are high concentration of salivary lysozyme in the mouth, low pH in the stomach and bile in the intestinal fluid (21). After 30, 90 and 120 minutes of lysozyme treatment, bacterial survival activity was shown in Fig. 5. Interestingly, among 20 isolates, only the KM50 and GM3-1 were sensitive (survival: 34.7% and 44.4%) to the lysozyme treatment after 120 min respectively. The rest of isolates exhibited resistance to lysozyme with resistance > 50%, among which 8 isolates showed severe resistance to the treatment of lysozyme (with resistance > 80%), which proved that Lactobacillus had high lysozyme tolerance. These eight isolates were selected for further research.

Resistance of acid and bile salt

The survival of Lactobacillus under low acid condition and high concentration of bile salt is of great significance to withstand gastrointestinal environment stress (22). Among 8, 5 isolates (KM66, KM86, KM147, Y3 and GM12-2) were resistant at pH 3.0 with resistance > 50%, and the maximum resistance were observed with KM66 (61.078%) and KM147 (61.077%), followed by the Y3 (55.205%) at pH 3.0. The above 3 isolates were also resistant to 0.3% of bile salt (survival: 75.291%, 62.940% and 65.049%) (Fig. 6).

Discussion

The 198 isolates of the isolated Lactobacillus belong to four species: *L. fermentum*, *L. brevis*, *L. oris*, and *L. vaginalis*. It has been reported that *L. fermentum* and *L. rhamnosus* were the most frequent species from breast milk at the level of species (23). In the present study, *L. fermentum* was the dominant species, which was the same as the results obtained by Soto et al. (24). Moreover, the present study also found that *L. fermentum* had 100% of relative abundance in colostrum. However, Ozgun et al. revealed that *L. brevis* was frequently found from colostrum samples from Turkey (25). This may be related to differences in region, the lifestyle and dietary habits of the mother. For colostrum A to mature milk B, the number and species of Lactobacillus isolated showed an uptrend,

mature milk B reached the highest level, and showed a downside from mature milk B to late milk E. Similar results were reported by Solis et al., who also found that the *Lactobacillus* spp. in mature milk (10–90 postpartum days) has higher isolation ratio and more species than colostrum (1 day) (26). It has been reported that the breast milk composition influence microbiota (27). Therefore, we can speculate that the growth of some *Lactobacillus* may be related to changes of nutrient composition in breast milk during different lactation periods. And mature milk is more suitable for *Lactobacillus* multiplication. In the present study, four isolates of *L. vaginalis* were rarely isolated from breast milk of stages B and C, which is seldom reported in other studies. Ana et al. detected *L. vaginalis* in only 2 of the 27 breast milk samples (24). This may be due to its harsh survival requirement or the introduction of new technologies, such as metagenomics and sequencing, which allowed the rapid development of *Lactobacillus* isolation. *Lactobacillus* are notoriously widespread in the skin, mouth cavity, gastrointestinal and vaginal cavities of humans (28). As previously reported, *L. vaginalis* was usually isolated from the vaginas of women (29). As demonstrated by Ramsay et al., a degree of reflux into the mammary duct during breast-feeding may facilitate the exchange of bacteria between mammary glands and the oral cavity of infants who acquire bacteria from the vaginal microbiome at birth (27). This shows that the presence of *L. vaginalis* in breast milk may be associated with vertical transmission during vaginal birth and breastfeeding.

Since the probiotic characteristics of *Lactobacillus* are specific to strains, the feasibility of exploring new strains is determined by these probiotic characteristics (30). The authors found that the isolates had strong antimicrobial activity. Notably, the KM66 exhibited a broad antimicrobial spectrum against all indicator pathogens and exhibited the broadest antimicrobial spectrum against *E. coli* (EPEC), *E. coli* (ETEC), *L. monocytogenes*, and *S. Typhimurium*. Mojgani et al. reported that *L. brevis* LB32 isolated from ewes' milk in Iran also exhibited a wide spectrum of inhibition against *L. monocytogenes* and *S. Typhimurium* (31). However, the KM15 with the same genotype as KM66 failed to inhibit *S. Enterica*. The Y3 (*L. fermentum*) exerted inhibition against all indicator pathogens. This result differs with the report done by Olivares et al., which indicated that *L. fermentum* CECT5716 isolated from human milk exhibited the suppression of *L. monocytogenes* and *E. coli* (ETEC), but failed to inhibit the growth of *E. coli* (EHEC) (32). The mechanism of the different antibacterial activities of these strains is largely determined by their different secreted antibacterial substances and the competition with pathogenic bacteria on nutrition and adhesion of intestinal epithelial cells (33–35).

The risk of *Lactobacillus* transmitting antibiotic-resistant genes to intestinal pathogens cannot be ignored. With regard to antibiotic resistance, 95% of isolates exhibited antibiotic resistance to vancomycin and co-trimoxazole, though the majority of isolates were found susceptible to other antibiotics. These results are similar with other research (36,37). Mohammadi et al. also showed that 94% of the *Lactobacillus* isolated from human milk were resistant to vancomycin (38). It has been reported that resistance to vancomycin and co-trimoxazole in certain *Lactobacillus* strains is not a safety issue since it is encoded by chromosomes rather than acquired, and therefore not transmissible (39). For safety assessment, the resistance to vancomycin can be used as a useful criterion for screening safe probiotic strains of *Lactobacillus* (40).

Ninety percent of candidates were tolerant to the lysozyme, suggesting that *Lactobacillus* had high lysozyme tolerance, which was confirmed by other authors (16, 41). However, only 3 isolates were substantially resistant to acid pH 3.0 and 0.3% of bile salt, respectively: KM66 (survival: 61.078%, 75.291%), KM147 (61.077%, 62.940%), and Y3 (55.205%, 65.049%). It indicates that these isolates could survive in the digestive tract. However, the KM26 with the same genotype as KM66 exhibited the lowest survival rate of 31.33% and 29.74% correspondingly at acid pH 3.0 and 0.3% of bile salt. The strains of *L. fermentum* isolated from human gastrointestinal tracts had relatively better acid tolerance in comparison to other species of *Lactobacillus* (22). Shokryazdan et al. also reported that the *L. fermentum* HM2 from human milk showed high acid tolerance at pH 3.0 with a resistance of 72.44%, but exhibited low tolerance to 0.3% of bile salt with a resistance of 20.42% (35), proving the specificity of the tolerance of strains. As reported, the *L. fermentum* CECT5716 isolated from breast milk was added as the probiotic and was found to reduce the incidence of gastrointestinal infection in infants after six months of continuous feeding (42). Additionally, Albesharat et al. demonstrated that *L. fermentum*, *L. brevis*, and *L. oris* were found in the mothers' milk and the faeces of the corresponding babies (43). In this study, the candidates are expected to colonize the intestine and inhibit the infection of pathogenic bacteria in infants.

Conclusion

The breast milk of Xinjiang Uyghur provided a rich source of *Lactobacillus*, the change trend of *Lactobacillus* population in breast milk was observable throughout lactation. The antibiotic resistance of the strains is low. Due to the specificity of the strain and safety considerations, Y3 (*L. fermentum* MG 551079) and KM147 (*L. brevis* KM495913) were regarded as candidate potential probiotics to be used in the food or healthcare industries. And they were isolated from mature milk B(15–150 days) and late milk E(451–750 days) respectively.

Methods

Isolation and identification of *Lactobacillus* spp.

Samples of breast milk were collected with the assistance of hospital doctors, and samples of mothers with underlying diseases were then removed. Strains were isolated and purified with modified MRS (de Man, Rogosa Sharp) medium (contains 0.5 g/L of L-cysteine). Based on morphology, rod-shaped bacterial colonies were cultured anaerobically at 37 °C for 24–48 h in an anaerobic glove box (80% N₂, 10% H₂ and 10% CO₂) (Shanghai jiehan co. LTD). All isolates were stored in –80 °C refrigerator with 20%–25% glycerine. Single colony DNA of isolates were extracted by method of CTAB (Cetyltriethylammonium Bromide) (44). Genomic fingerprinting rep-PCR was amplified using primer BOXAIR (5'CTACGGCAAGGCGACGCTGAC3'), and the augmented system is shown in Table 4. The PCR products were electrophoresed on 1% ~ 1.2% agarose gel about 40 min 100V(2.5 V/cm), imaged on observation(CCD camera Biometra Gel DOC XR). Universal primers 27f and 1492R were used for 16S r RNA partial gene sequencing (45). The 16S r RNA gene sequences were retrieved from the National Center for Biotechnology Information (NCBI) database. Sequences with similarities above 97% in BLAST database were identified.

Method	Primer	Mix	Augmented system	Amplification procedure
BOX-PCR	BOXAIR (CTACGGCAAGGCGACGCTGAC)	10×buffer Taq enzyme dNTP	Mix: 12.5µL BOX: 0.5µL Double distilled water: 9.5µL Template DNA: 1.5µL	Initial denaturation: 95°C 5min Degeneration: 94°C 1min Annealing: 52°C 1min Extention: 65°C 8min Eventual extention: 65°C 16min (35 Cycles: 6h 30min)

Table 4
Rep-PCR amplification system

Assessment of antimicrobial activity

Antimicrobial activity of *Lactobacillus* against pathogens was detected by the modified sandwich overlay method as described (46). The 100 µl bacterial suspension of each bacterium (10^7 - 10^8 CFU/ml) was dispensed into MRS medium well and cultured at 37 °C for 24 h under the anaerobic condition. Pathogens purchased from China Industrial Microbial Species Preservation and Management Center (including *E. coli* (EPEC) O127:K63, *S. Typhimurium*, *E. coli* (ETEC) O78:K80, *E. coli* (EHEC) O157:H7, *L. monocytogenes* and *S. Enterica*) were incubated at 37 °C for 16 h, then 100 µl of suspension was uniformly coated with sterile cotton swab. The agar covered with isolates colonies was drilled with a hole punch (diameter:7 mm) and the agar blocks were immediately placed onto each indicator pathogen plate. The inhibition zone diameter, which inhibited the growth of pathogens obviously near the colony was measured and the results were divided into < 10, 10–20 and > 20 mm. MRS agar was taken as the negative control and assays were carried out in quadruplication.

Antibiotic resistance

The antibiotic resistance profiles of isolates were determined by the K-B paper method with the following 8 different types of antibiotics tablets: penicillin-G (10 µg), gentamicin (120 µg), rifampicin (5 µg), ampicillin (10 µg), cotrimoxazole (25 µg), vancomycin (30 µg), tetracycline (30 µg) and chloramphenicol (30 µg). The 100 µl of bacterial suspension (10^7 - 10^8 CFU/ml) were spread over the plates, and these tablets were placed onto the agar surface. Then plates were cultivated at 37 °C anaerobically for 24 h and the diameter of its inhibition zone was measured with calibrated scale. The drug tablets were purchased from the British company OXOID. The results of drug susceptibility were determined according to CLSI standard and were identified as sensitive (S), mediating (I) and resistant (R) (47). Assays were carried out triplicate.

Resistance of lysozyme

Likewise, bacterial inoculum (10^7 - 10^8 CFU/ml) were centrifuged at 4000 rpm for 5 min and washed thrice with phosphate buffer (pH7, 0.1M) and resuspended. Subsequently, 0.2 ml of cell suspension was transferred to 10 ml of MRS broth containing lysozyme (0.1 g/L) separately. Meanwhile, MRS broth was taken as positive control. The optical density at 600 nm (OD_{600nm}) was measured by ELIASA after incubating anaerobically at 37 °C for 30, 90 and 120 minutes and compared with that without treatment. The % resistance = the residual quantity of OD_{600nm} in MRS broth with different concentrations of lysozyme / increment of OD_{600nm} in MRS broth without lysozyme. The results were divided into three categories: the survival % > 80% after 120 min of cultivation, which could be considered a severe resistance to lysozyme, 50% ~ 80% of survival was considered moderate resistance and < 50% as sensitive to lysozyme (48). The experiments were carried out triplicate.

Resistance of acid and bile salt

Briefly, 0.2 ml of bacterial inoculum (10^7 - 10^8 CFU/ml) was added to 10 ml of MRS liquid medium adjusted to pH 2, 3, and 4 by 36% hydrochloric acid respectively. OD_{600nm} was measured after anaerobic incubation at 37 °C for 16 h against the positive control (pH 7.0). *Lactobacillus* isolates showing resistance more than 50% at pH 3 were considered as acid resistant (49). Similarly, 0.2 ml of each bacteria solution (10^7 - 10^8 CFU/ml) was transferred to 10 ml of MRS broth containing different concentrations of pig bile salt (0.3%, 0.5% and 1.0% w/v) against the control (without bile salt). The broth were incubated at 37 °C for 16 h, then the OD_{600nm} were measured. *Lactobacillus* isolates at the minimum resistance range of 50% at 0.3% (w/v) bile salt were considered as bile resistant (50). The % resistance = the residual quantity of OD_{600nm} in MRS broth with different concentrations of bile salt or pH (2,3,4) / increment of OD_{600nm} in MRS broth without bile salt or pH (7) × 100. Assays were carried out in triplicate.

Abbreviations

LAB
lactic acid bacteria
16SrRNA
16S ribosomal ribonucleic acid

rep-PCR
repetitive genomic fingerprinting PCR
OD
Optical density
spp
Species

Declarations

Ethics approval and consent to participate

All participants gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Human Research Ethics Boards at Shihezi University, Xinjiang. Samples of breast milk were collected with the assistance of hospital doctors, and samples of mothers with suspected diseases were then removed.

Consent for publication

Not applicable

Availability of data and materials

All data and materials are available on request for academic use. No administrative permission is required but approval from a local hospital is required to obtain breast milk samples from healthy individuals. The individuals mentioned in the method had no associated disease. The 16S rRNA gene sequence can be submitted to the National Center for Biotechnology Information (NCBI) database.

Competing interests

The authors declare that they have no conflict of interests.

Funding

This work was supported by the joint key funds of the National Natural Science Foundation of China and Autonomous Region Government of Xinjiang (Grant. No.U1903205) and the National Natural Science Foundation of China (Grant. NO. 31760446). The funder had no role in the study design and collection, analysis of data, preparation of the manuscript or decision to publish.

Authors' contributions

YQ and FW conceived the study. YQ participated in the experimental design. Manuscript was written by XJ and edited by YQ, XL and YZ. Each author informed the consent to participate of this publication.

Acknowledgements

Not applicable

References

1. Klein G, Pack A, Bonaparte C, Reuter G. Taxonomy and physiology of probiotic lactic acid bacteria. *Int J Food Microbiol.* 1998; 1(2):103-125. [https://doi.org/10.1016/s0168-1605\(98\)00049-x](https://doi.org/10.1016/s0168-1605(98)00049-x).
2. Carr FJ, Chill D, Maida N. The lactic acid bacteria: a literature survey. *Crit Rev Microbiol.* 2002; 28(4):281-370. <https://doi.org/10.1080/1040-840291046759>.
3. Cross ML. Immunoregulation by probiotic lactobacilli- pro-Th1 signals and their relevance to human health. *Clin Appl Immunol Rev.* 2002; 3(3):115-125. [https://doi.org/10.1016/S1529-1049\(02\)00057-0](https://doi.org/10.1016/S1529-1049(02)00057-0).
4. Neethu J, Craig B, Malik H. Comparison of Microbiological and Probiotic Characteristics of Lactobacilli Isolates from Dairy Food Products and Animal Rumen Contents. *Microorganisms.* 2015; 3(2):198-212. <https://doi.org/10.3390/microorganisms3020198>.
5. Selle K, Klaenhammer TR. Genomic and phenotypic evidence for probiotic influences of *Lactobacillus gasser* on human health. *FEMS Microbio Rev.* 2013; 37(6):915-935. <https://doi.org/10.1111/1574-6976.12021>.
6. Civardi E, Garofoli F, Tzialla C, Paolillo P, Bollani L, Stronati M. Microorganisms in human milk: lights and shadows. *J Matern-Fetal Neo M.* 2013; 26(S2):30-34. <https://doi.org/10.3109/14767058.2013.829693>.
7. Martín R, Langa S, Reviriego C, Reviriego C, Jiménez E, Marín ML, Xaus J. Human milk is a source of lactic acid bacteria for the infant gut. *Pediatrics.* 2003; 143(6):0-758. <https://doi.org/10.1016/j.jpeds.2003.09.028>.
8. Pe´rez-Cano FJ, Dong H, Yaqoob P. In vitro immunomodulatory activity of *Lactobacillus fermentum* CECT5716 and *Lactobacillus salivarius* CECT5713: two probiotic strains isolated from human breast milk. *Immunobiology.* 2010; 215:996–1004. <https://doi.org/10.1016/j.imbio.2010.01.004>.
9. Leónides F, Langa S, Martín V, Maldonado A, Jiménez E, Martín R, Rodríguez JM. The human milk microbiota: Origin and potential roles in health and diseases. *Pharmacol Res.* 2013; 69(1):1-10. <https://doi.org/10.1016/j.phrs.2012.09.001>.

10. Duijts L, Jaddoe VWV, Hofman A, Moll HA. Prolonged and Exclusive Breastfeeding Reduces the Risk of Infectious Diseases in Infancy. *Pediatrics*. 2010; 126(1):e18-e25. <https://doi.org/10.1542/peds.2008-3256>.
11. Listed NA. Breastfeeding and the use of human milk. American Academy of Pediatrics. Work Group on Breastfeeding. *Pediatrics*. 1997; 100(6):1035-1039.
12. Martín R, Olivares M, Marín ML, Xaus J, Fernández L, Rodríguez JM. Characterization of a reuterin-producing lactobacillus coryniformis strain isolated from a goat's milk cheese. *Int J Food Microbiol*. 2005; 104(3):267-277. <https://doi.org/10.1016/j.ijfoodmicro.2005.03.007>.
13. Lara-Villoslada F, Sierra S, Díaz-Ropero, Paz M, Rodríguez, Miguel J, Xaus J, Olivares M. Safety Assessment of *Lactobacillus fermentum* CECT5716, a probiotic strain isolated from human milk. *J Dairy Res*. 2009; 76(02):216. <https://doi.org/10.1017/S0022029909004014>.
14. Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. *Proc Natl Acad Sci USA*. 2010; 107(26):11971-11975.
15. Madan JC, Hoen AG, Lundgren SN, Farzan SF, Cottingham KL, Morrison HG. Association of cesarean del and formula supplementation with the intestinal microbiome of 6-Week-infants. *Jama Pediatrics*. 2016; 170(3):212-219. <https://doi.org/10.1001/jamapediatrics.2015.3732>.
16. Ilcol YO, Hizli ZB, Ozkan T. Leptin concentration in breast milk and its relationship to duration of lactation and hormonal status. *Int Breastfeed J*. 2006; 1(1):21. <https://doi.org/10.1186/1746-4358-1-21>.
17. Do NMBR, Hugo I. Breastfeeding: making the difference in the development, health and nutrition of term and preterm newborns. *Revista do Hospital das Clínicas*. 2003; 58(1):49-60. <https://doi.org/10.1590/S0041-87812003000100010>.
18. Saarela M. Probiotic bacteria: safety, functional and technological properties. *J Biotechnol*. 2000; 84. [https://doi.org/10.1016/S0168-1656\(00\)00375-8](https://doi.org/10.1016/S0168-1656(00)00375-8).
19. Corcoran BM, Stanton C, Fitzgerald GF, Ross RP. Survival of Probiotic Lactobacilli in Acidic Environments Is Enhanced in the Presence of Metabolizable Sugars. *Appl Environ Microbiol*. 2005; 71(6):3060-3067. <https://doi.org/10.1128/aem.71.6.3060-3067.2005>.
20. Curto AL, Pitino I, Mandalari G, Dainty JR, Faulks RM, Wickham MSJ. Survival of probiotic lactobacilli in the upper gastrointestinal tract using an in vitro gastric model of digestion. *Food Microbiology*. 2011; 28(7):1359-1366. <https://doi.org/10.1016/j.fm.2011.06.007>.
21. Corzo G, Gilliland SE. Bile Salt Hydrolase Activity of Three Strains of *Lactobacillus acidophilus*. *J Dairy Sci*. 1999; 82(3):472. [https://doi.org/10.3168/jds.s0022-0302\(99\)75256-2](https://doi.org/10.3168/jds.s0022-0302(99)75256-2).
22. Kumar A, Kumar D. Characterization of *Lactobacillus* isolated from dairy samples for probiotic properties. *Anaerobe*. 2015; 33:117-123. <https://doi.org/10.1016/j.anaerobe.2015.03.004>.
23. Martin V, Maldonado-Barragan A, Moles L, Rodriguez-Banos M, Campo RD, Fernandez L. Sharing of Bacterial Strains Between Breast Milk and Infant Feces. *Journal of Human Lactation*. 2012; 28(1):36-44. <https://doi.org/10.1177/0890334411424729>.
24. Soto A, Martín V, Jiménez E, Mader I, Fernández L. Lactobacilli and Bifidobacteria in Human Breast Milk: Influence of Antibiotherapy and Other Host and Clinical Factors. *J Pediatr Gastr Nutr*. 2014; 59(1):78-88. <https://doi.org/10.1097/MPG.0000000000000347>.
25. Ozgun D, Vural HC. Identification of *Lactobacillus* strains isolated from faecal specimens of babies and human milk colostrum by API 50 CHL system. *Journal of Medical Genetics and Genomics Vol*. 2011; 3(3):46 - 49.
26. Solís G, Reyes-Gavilan CGDL, Fernández N, Margolles A, Gueimonde M. Establishment and development of lactic acid bacteria and bifidobacteria microbiota in breast-milk and the infant gut. *Anaerobe*. 2010; 16(3):307-310. <https://doi.org/10.1016/j.anaerobe.2010.02.004>.
27. Jeurink PV, Van BJ, Jiménez E, Knippels LM, Fernández L, Garssen J. Human milk: a source of more life than we imagine. *Benef Microbes*. 2013; 4(1):17-30. <https://doi.org/10.3920/BM2012.0040>.
28. Benavides AB, Ulcuango M, Yépez, Lucía, Tenea GN. Assessment of the in vitro bioactive properties of lactic acid bacteria isolated from native ecological niches of Ecuador. *Rev Argent Microbiol*. 2016; 48(3):236-244. <https://doi.org/10.1016/j.ram.2016.05.003>.
29. Teixeira GS, Carvalho FP, Arantes RME, Nunes AC, Moreira JLS, Mendonca M. Characteristics of *Lactobacillus* and *Gardnerella vaginalis* from women with or without bacterial vaginosis and their relationships in gnotobiotic mice. *J Med Microbiol*. 2012; 61(Pt_8):1074-1081. <https://doi.org/10.1099/jmm.0.041962-0>.
30. Ramos CL, Thorsen L, Schwan RF, Jespersen L. Strain-specific probiotics properties of *Lactobacillus fermentum*, *Lactobacillus plantarum* and *Lactobacillus brevis* isolates from Brazilian food products. *Food Microbiology*. 2013; 36(1):22-29. <https://doi.org/10.1016/j.fm.2013.03.010>.
31. Mojgani N, Hussaini F, Vaseji N. Characterization of Indigenous *Lactobacillus* Strains for Probiotic Properties. *Jundishapur J Microb*. 2015; 8(2).
32. Olivares M, Díaz-Ropero MP, Martín R. Antimicrobial potential of four *Lactobacillus* strains isolated from breast milk. *J Appl Microbiol*. 2006; 101(1). <https://doi.org/10.1111/j.1365-2672.2006.02981.x>.
33. Bourlioux P, Koletzko B, Guarner F. The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium "The Intelligent Intestine," held in Paris, June 14. *Am J Clin Nutr*. 2003; 78(4):675-683. <https://doi.org/10.1093/ajcn/78.4.675>.
34. Servin AL. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. *Fems Microbiol Rev*. 2010; 28(4):405-440. <https://doi.org/10.1016/j.femsre.2004.01.003>.
35. Shokryazdan P, Sieo CC, Kalavathy R, Liang JB, Ho YW. Probiotic Potential of *Lactobacillus* Strains with Antimicrobial Activity against Some Human Pathogenic Strains. *Biomed Res Int*. 2014; 2014(2):927268. <https://doi.org/10.1155/2014/927268>.
36. Maragkoudakis PA, Zoumpopoulou G, Miaris C, Kalantzopoulos G, Pot B, Tsakalidou E. Probiotic potential of *Lactobacillus* strains isolated from dairy products. *Int Dairy J*. 2006; 16(3):0-199. <https://doi.org/10.1016/j.idairyj.2005.02.009>.
37. Nikolaeva IV, Shabanova NA, Bondarenko VM, Konovalova GN, Anokhin VA. [Species composition and antibiotic resistance of *Lactobacillus* in infants]. *Zh Mikrobiol Epidemiol Immunobiol*. 1900; (6):70-5.

38. Mohammadi F, Eshaghi M, Razavi S, Sarokhalil DD, Talebi M, Pourshafie MR. Characterization of bacteriocin production in *Lactobacillus* spp. isolated from mother's milk. *Microbial Pathogenesis*. 2018. <https://doi.org/10.1016/j.micpath.2018.03.020>.
39. Ammor MS, Flórez AB, Mayo B. Antibiotic resistance in non-enterococcal lactic acid bacteria and bifidobacteria. *Food Microbiology (London)*. 2007; 24(6):559-570. <https://doi.org/10.1016/j.fm.2006.11.001>.
40. Klein G. Antibiotic Resistance and Molecular Characterization of Probiotic and Clinical *Lactobacillus* Strains in Relation to Safety Aspects of Probiotics. *Foodborne Pathog Dis*. 2011; 8(2):267-281. <https://doi.org/10.1089/fpd.2010.0672>.
41. Turchi B, Simone Mancin. Preliminary evaluation of probiotic potential of *Lactobacillus plantarum* strains isolated from Italian food products. *World J Microbiol Biot*. 2013; 29(10):1913-1922. <https://doi.org/10.1007/s11274-013-1356-7>.
42. Maldonado, José, Cañabate, Francisco, Sempere L, Vela F, Sánchez Ana R, Narbona E. Human Milk Probiotic *Lactobacillus fermentum* CECT5716 Reduces the Incidence of Gastrointestinal and Upper Respiratory Tract Infections in Infants. *J Pediatr Gastr Nutr*. 2012; 54(1):55. <https://doi.org/10.1097/MPG.0b013e3182333f18>
43. Albesharat R, Ehrmann MA, Korakli M, Yazaji S, Vogel RF. Phenotypic and genotypic analyses of lactic acid bacteria in local fermented food, breast milk and faeces of mothers and their babies. *Sys Appl Microbiol*. 2011; 34(2):148-155. <https://doi.org/10.1016/j.syapm.2010.12.001>.
44. Medium Optimization for Producing Gamma-aminobutyric Acid by the Fermentation of *Lactobacillus brevis* BS2 with Zinc-enriching ability and Cloning and Sequencing of Its Glutamate Decarboxylase Gene. *Food Science*. 2010; 31(19):304-308. <https://doi.org/10.1017/S0004972710001772>.
45. Stackebrandt E, Goodfellow M. *Nucleic acid techniques in bacterial systematics*. 1991.
46. Rodríguez E, González B, Gaya P, Nuñez M, Medina M. Diversity of bacteriocins produced by lactic acid bacteria isoated from raw milk. *Int Dairy J*. 2000; 10(1):7-15. [https://doi.org/10.1016/S0958-6946\(00\)00017-0](https://doi.org/10.1016/S0958-6946(00)00017-0).
47. Jones RN. NCCLS guidelines: revised performance standards for antimicrobial disk susceptibility tests. *Antimicrobial Newsletter*. 1984; 1(8):64-65. [https://doi.org/10.1016/0738-1751\(84\)90027-3](https://doi.org/10.1016/0738-1751(84)90027-3).
48. Zago M, Fornasari ME, Carminati D, Burns P, Suárez V, Vinderola G. Characterization and probiotic potential of *Lactobacillus plantarum* strains isolated from cheeses. *Food Microbiol*. 2011; 28(5):1033-1040. <https://doi.org/10.1016/j.fm.2011.02.009>.
49. Sieladie DV, Zambou NF, Kaktcham PM, Cresci A, Fonteh F. Probiotic properties of lactobacilli strains isolated from raw cow milk in the western highlands of cameroon. *Innov Rom Food Biotechnol*. 2011; 9:12-28.
50. Vinderola CG, Reinheimer JA. Lactic acid starter and probiotic bacteria: a comparative "in vitro" study of probiotic characteristics and biological barrier resistance. *Food Res Int*. 2003; 36(9-10):0-904. [https://doi.org/10.1016/s0963-9969\(03\)00098-x](https://doi.org/10.1016/s0963-9969(03)00098-x).

Figures




Figure 1

Relative abundance of Lactobacillus species in different lactation period




Figure 2

Principal component analysis of *Lactobacillus* population structure in different lactation stages




Figure 3

Dendrogram depicting of 33 Lactobacillus isolates based on rep-PCR




Figure 4

Antibiotic resistance rate of Lactobacillus from breast milk




Figure 5

Effect of lysozyme treatment on the viability of Lactobacillus




Figure 6

Effect of different acid pH values and bile salt concentration on survival of Lactobacillus isolates